Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,923 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Buzdar AU, et al. Among authors: green mc. J Clin Oncol. 2005 Jun 1;23(16):3676-85. doi: 10.1200/JCO.2005.07.032. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738535 Clinical Trial.
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Green MC, et al. J Clin Oncol. 2005 Sep 1;23(25):5983-92. doi: 10.1200/JCO.2005.06.232. Epub 2005 Aug 8. J Clin Oncol. 2005. PMID: 16087943 Clinical Trial.
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Bianchini G, et al. Among authors: green mc. J Clin Oncol. 2010 Oct 1;28(28):4316-23. doi: 10.1200/JCO.2009.27.2419. Epub 2010 Aug 30. J Clin Oncol. 2010. PMID: 20805453
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.
Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Kelly CM, et al. Among authors: green mc. J Clin Oncol. 2012 Mar 20;30(9):930-5. doi: 10.1200/JCO.2011.36.2079. Epub 2012 Feb 13. J Clin Oncol. 2012. PMID: 22331946 Clinical Trial.
Neoadjuvant chemotherapy for operable breast cancer.
Green M, Hortobagyi GN. Green M, et al. Oncology (Williston Park). 2002 Jul;16(7):871-84, 889; discussion 889-90, 892-4, 897-8. Oncology (Williston Park). 2002. PMID: 12164555 Free article. Review.
Adjuvant chemotherapy for breast cancer.
Green MC, Hortobagyi GN. Green MC, et al. Langenbecks Arch Surg. 2002 Jul;387(3-4):109-116. doi: 10.1007/s00423-002-0288-8. Langenbecks Arch Surg. 2002. PMID: 12269263 Review.
7,923 results